PTCT
Ptc Therapeutics, Inc.
$78.84
+0.78 (+1.00%)
At close · Jul 15
Market Cap
$6.48B
Shares
82,949,338
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.73B
+114.5%
FY2025
Net Income
$682.64M
+287.9%
FY2025
Gross Margin
96.05%
FY2019
Operating Margin
50.09%
+87.6pp
FY2025
Diluted EPS
$7.78
+264.5%
FY2025
Operating Cash Flow
$711.2M
+760.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $827.11M | $1.73B | $806.78M | $937.82M | $698.8M | $538.59M | $380.77M | $306.98M | $264.73M | $194.39M | $82.71M | $36.77M | $25.25M | $34.7M | |
| — | — | — | — | — | — | — | $12.14M | — | $4.58M | — | — | — | — | |
| — | — | — | — | — | — | — | $294.85M | — | $189.82M | — | — | — | — | |
| — | — | — | — | — | — | — | 96.05% | — | 97.65% | — | — | — | — | |
| $447.15M | $455.25M | $534.48M | $666.56M | $651.5M | $540.68M | $477.64M | $257.45M | $171.98M | $117.46M | $117.63M | $121.82M | $79.84M | $54.88M | |
| — | — | — | — | — | — | — | — | — | $121.27M | $97.13M | $82.08M | $44.82M | $25.22M | |
| $352.37M | $347.14M | $300.91M | $332.54M | $326M | $285.77M | $245.16M | $202.54M | $153.55M | — | — | — | — | — | |
| $32.53M | $24.74M | $60.74M | $222.64M | $116.55M | $54.75M | $36.89M | $27.65M | $22.88M | $15.38M | — | — | — | — | |
| — | $38.82M | $75.66M | $236.59M | $128.84M | $64.13M | $43.49M | $32.18M | $26.09M | $17.68M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $0 | — | — | — | — | |
| $885.44M | $863.72M | $1.11B | $1.38B | $1.15B | $913.04M | $812.53M | $548.14M | $380.42M | $258.68M | $214.76M | $203.9M | $124.66M | $80.09M | |
| -$58.33M | $866.94M | -$302.57M | -$439.5M | -$447.41M | -$374.44M | -$431.77M | -$241.16M | -$115.69M | -$64.29M | -$132.06M | -$167.13M | -$99.41M | -$45.4M | |
| — | 50.09% | -37.5% | -46.86% | -64.03% | -69.52% | -113.39% | -78.56% | -43.7% | -33.07% | -159.67% | -454.58% | -393.79% | -130.84% | |
| — | $905.75M | -$226.91M | -$202.91M | -$318.57M | -$310.31M | -$388.28M | -$208.98M | -$89.6M | -$46.61M | — | — | — | — | |
| -$10.17M | -$18.09M | $6.54M | $10.13M | -$49.21M | -$57.88M | $85.19M | $13.72M | $129K | -$1.28M | -$1.21M | -$465K | -$213K | $37.51K | |
| -$235.67M | $696.62M | -$363.12M | -$696.11M | -$587.49M | -$518.34M | -$402.93M | -$239.93M | -$128.11M | -$77.67M | -$141.54M | -$169.96M | -$98.45M | -$51.57M | |
| -$48.94M | $13.98M | $176K | -$69.51M | -$28.47M | $5.56M | $35.23M | $11.65M | -$29K | $1.34M | $569K | $485K | -$4.69M | -$2.31M | |
| -$186.73M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | -$251.58M | -$128.08M | -$79M | -$142.11M | -$170.45M | -$93.75M | -$51.57M | |
| — | 39.44% | -45.03% | -66.81% | -80% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.6% | -371.37% | -148.64% | |
| -$186.73M | $682.64M | -$363.3M | -$626.6M | -$559.02M | -$523.9M | -$438.16M | — | — | — | — | -$170.45M | -$93.75M | -$66.43M | |
| -$164.31M | $719.03M | -$387.9M | -$632.69M | -$529.94M | -$487.23M | -$488.53M | -$263.62M | -$130.59M | -$73.55M | -$142.4M | -$170.91M | -$94.56M | -$51.5M | |
| USD/shares | — | $8.58 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | — | -$4.27 | — | — | — | — | -$2.97 | -$5.18 |
| USD/shares | — | $7.78 | -$4.73 | -$8.37 | -$7.79 | -$7.43 | — | — | — | — | — | — | -$2.97 | -$5.18 |
| shares | — | 79.53M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M |
| shares | — | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.15×
P/E (TTM)
—
Biotechnology median 7.35×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Life Science Segment | $1,730,655,000 | $806,780,000 | $937,822,000 | $698,801,000 |
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $252,185,000 | $207,215,000 | $255,087,000 | $381,862,000 | $297,005,000 | $186,396,000 | $116,676,000 | $93,694,000 |
| Non Us | $235,888,000 | $393,736,000 | $406,161,000 | $316,939,000 | $241,588,000 | $194,370,000 | $190,304,000 | $171,040,000 |
| All Other Countries Other Than Russia Brazil And United States | $168,412,000 | $197,472,000 | $238,510,000 | — | — | — | — | — |
| Russia | $100,445,000 | $105,377,000 | $85,974,000 | — | — | — | — | — |
| Brazil | $65,661,000 | $72,081,000 | $58,606,000 | — | — | — | — | — |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Collaboration and License Revenue | $998,357,000 | $304,000 | $100,030,000 | — | — | — | — | — |
| Product | $586,703,000 | $582,145,000 | $638,177,000 | $535,228,000 | $428,904,000 | $333,401,000 | $291,306,000 | $263,005,000 |
| Royalty | $244,224,000 | $203,864,000 | $168,856,000 | $113,521,000 | $54,643,000 | $4,786,000 | — | — |
| Translarna1 | $235,299,000 | $321,071,000 | $332,753,000 | — | — | — | — | — |
| Emflaza | $146,361,000 | $207,215,000 | $255,087,000 | — | — | — | — | — |
| Sephience | $111,153,000 | — | — | — | — | — | — | — |
| Upstaza and Kebilidi | $56,626,000 | $16,913,000 | $18,841,000 | — | — | — | — | — |
| Other Products | $37,264,000 | $36,946,000 | $31,496,000 | — | — | — | — | — |
| Translarna | -$98,629,000 | $18,806,000 | $23,072,000 | — | — | — | — | — |
| Collaboration Revenue | — | $304,000 | $100,030,000 | $50,052,000 | $55,046,000 | — | — | — |
| Grant And Collaboration | — | — | — | — | — | $42,579,000 | $15,674,000 | $1,729,000 |
| Manufacturing | — | $1,661,000 | $7,687,000 | — | — | — | — | — |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
26 filings
25 filers
Visit website
Investor relations